Prediction of MET Overexpression in Lung Adenocarcinoma from Hematoxylin and Eosin Images

MET protein overexpression is a targetable event in non-small cell lung cancer (NSCLC) and is the subject of active drug development. Challenges in identifying patients for these therapies include lack of access to validated testing, such as standardized immunohistochemistry (IHC) assessment, and consumption of valuable tissue for a single gene/protein assay. Development of pre-screening algorithms using routinely available digitized hematoxylin and eosin (H&E)-stained slides to predict MET overexpression could promote testing for those who will benefit most.

Source: American Journal of Pathology - March 15, 2024 Category: Pathology Authors: Kshitij Ingale, Sun Hae Hong, Josh S.K. Bell, Abbas Rizvi, Amy Welch, Lingdao Sha, Irvin Ho, Kunal Nagpal, A ïcha Bentaieb, Rohan P. Joshi, Martin C. Stumpe Tags: Regular Article Source Type: research